logo
  Join        Login             Stock Quote

Psivida (PSDV): Iluvien To Treat Chronic Diabetic Macular Edema Gets Marketing Authorization In UK

 May 07, 2012 09:37 AM


(By Balaseshan) pSivida Corp. (NASDAQ:PSDV), which develops drug delivery products, said the Iluvien to treat chronic diabetic macular edema has received marketing authorization in the United Kingdom.

Additional CMS marketing authorizations are expected in the coming months and Alimera Sciences Inc. (NASDAQ:ALIM) has reported it continues to expect Iluvien to be available in the European Union by the end of 2012.

The Medicines and Healthcare products Regulatory Agency of the United Kingdom (MHRA) has granted marketing authorization for Iluvien for the treatment of vision impairment associated with chronic diabetic macular edema (DME) considered insufficiently responsive to available therapies.

[Related -Six Stocks That Could Get An October Bump From The FDA]

Iluvien is an injectable, sustained-release intravitreal insert that releases sub-microgram levels of fluocinolone acetonide (FAc) for up to 36 months for the treatment of chronic DME. pSivida is developing an insert of the same design for the treatment of uveitis affecting the posterior of the eye.

This marketing authorization follows the recently announced approval in Austria. These approvals were preceded by completion of the Decentralized Regulatory Procedure (DCP) in the European Union (EU), in which the MHRA, serving as the Reference Member State (RMS), delivered a positive outcome for Iluvien along with six Concerned Members States, specifically Austria, France, Germany, Italy, Spain and Portugal.

[Related -Stock Market Opening Report: September 14, 2012]

The International Diabetes Federation expects that more than 3 million people are currently living with diabetes in the U.K., and Alimera estimates, nearly 200,000 suffer with vision loss from DME.

Alimera has reported it is currently in advanced discussions with the U.K.'s National Institute for Health and Clinical Excellence (NICE) to provide guidance to the National Health Service on the reimbursement of Iluvien.

PSDV is trading up 5.66% at $2.24 on Monday. The stock has been trading between $1.02 and $5.23 for the past 52 weeks.

iOnTheMarket Premium
Advertisement

Advertisement


Post Comment -- Login is required to post message
Name:  
Alert for new comments:
Your email:
Your Website:
Title:
Comments:
 

rss feed

Latest Stories

article imageShould You Invest In The Hottest New Trend In Finance?

Thanks to major changes in regulation, social media and technology, the business of banking has undergone read on...

article imageStrong Attractor in Action Pulling S&P 500 Down

The attractor is formed by the 200-day moving average and the 50% Fibonacci retracement of the up move from read on...

article imageIs The Weak Housing Market A Warning Sign For The US Economy?

Today’s US economic releases – housing starts and business survey data for the manufacturing sector – read on...

article imageShort-term Pullback or Something Worse?

A few weeks ago when we called for a short-term pullback of 4 to 5%, it was due solely to the short-term read on...

Advertisement
Popular Articles

Advertisement
Daily Sector Scan
Partner Center



Fundamental data is provided by Zacks Investment Research, and Commentary, news and Press Releases provided by YellowBrix and Quotemedia.
All information provided "as is" for informational purposes only, not intended for trading purposes or advice. iStockAnalyst.com is not an investment adviser and does not provide, endorse or review any information or data contained herein.
The blog articles are opinions by respective blogger. By using this site you are agreeing to terms and conditions posted on respective bloggers' website.
The postings/comments on the site may or may not be from reliable sources. Neither iStockAnalyst nor any of its independent providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein. You are solely responsible for the investment decisions made by you and the consequences resulting therefrom. By accessing the iStockAnalyst.com site, you agree not to redistribute the information found therein.
The sector scan is based on 15-30 minutes delayed data. The Pattern scan is based on EOD data.